Cidara Therapeutics Inc (CDTX)
13.43
+0.40
(+3.07%)
USD |
NASDAQ |
Nov 05, 16:00
13.43
0.00 (0.00%)
After-Hours: 19:04
Cidara Therapeutics Debt to Equity Ratio: 0.00 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | -0.0465 |
| March 31, 2022 | 0.2988 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.1201 |
| September 30, 2021 | -3.195 |
| June 30, 2021 | 0.3045 |
| March 31, 2021 | 3.127 |
| December 31, 2020 | 0.6554 |
| September 30, 2020 | 0.2751 |
| June 30, 2020 | 0.2233 |
| March 31, 2020 | 0.1854 |
| December 31, 2019 | 0.2634 |
| September 30, 2019 | 0.2034 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.195
Minimum
Sep 2021
3.127
Maximum
Mar 2021
0.1164
Average
--
Median
Sep 2022
Debt to Equity Ratio Benchmarks
| Biomarin Pharmaceutical Inc | 0.1098 |
| Arbutus Biopharma Corp | 0.00 |
| GlycoMimetics Inc | -- |
| FibroGen Inc | -0.3119 |
| Cue Biopharma Inc | 0.289 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 173.36M |
| Total Liabilities (Quarterly) | 42.42M |
| Shareholders Equity (Quarterly) | 130.94M |
| Current Ratio | 4.253 |